Abvc Biopharma Stock Today
| ABVC Stock | USD 1.45 0.03 2.11% |
PerformanceWeakest
| Odds Of DistressRisky
|
ABVC Biopharma is trading at 1.45 as of the 4th of March 2026, a 2.11 percent increase since the beginning of the trading day. The stock's open price was 1.42. ABVC Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 4th of December 2025 and ending today, the 4th of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2017 | Category Healthcare | Classification Health Care |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 24.3 M outstanding shares of which 247.74 K shares are presently shorted by private and institutional investors with about 4.52 trading days to cover. More on ABVC Biopharma
Moving together with ABVC Stock
Moving against ABVC Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
ABVC Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, ABVC Biopharma can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on ABVC Biopharma's use of financial leverage and reveals what portion of ABVC Biopharma's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma (ABVC) is traded on NASDAQ Exchange in USA and employs 16 people. ABVC Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.97 M. ABVC Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.3 M outstanding shares of which 247.74 K shares are presently shorted by private and institutional investors with about 4.52 trading days to cover.
ABVC Biopharma currently holds about 2.99 M in cash with (1.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check ABVC Biopharma Probability Of Bankruptcy
Ownership AllocationABVC Biopharma holds a total of 24.3 Million outstanding shares. ABVC Biopharma shows 10.7 percent of its outstanding shares held by insiders and 3.33 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ABVC Ownership Details
ABVC Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Simplex Trading, Llc | 2025-09-30 | 1.1 K | |
| Bank Of America Corp | 2025-09-30 | 175 | |
| Northwestern Mutual Wealth Management Co | 2025-09-30 | 150 | |
| Sbi Securities Co Ltd | 2025-09-30 | 0.0 | |
| Vanguard Group Inc | 2025-12-31 | 287.9 K | |
| Geode Capital Management, Llc | 2025-09-30 | 187.8 K | |
| Renaissance Technologies Corp | 2025-12-31 | 114.3 K | |
| State Street Corp | 2025-09-30 | 72.8 K | |
| Blackrock Inc | 2025-09-30 | 56.4 K | |
| Northern Trust Corp | 2025-09-30 | 24.8 K | |
| Xtx Topco Ltd | 2025-09-30 | 24.8 K |
ABVC Biopharma Historical Income Statement
ABVC Stock Against Markets
ABVC Biopharma Corporate Management
| TsungShann Jiang | Member Officer | Profile | |
| Leeds Chow | Chief Officer | Profile | |
| Howard MD | Pres CEO | Profile | |
| ChiHsin King | Chief Officer | Profile | |
| Uttam Patil | Chief Officer | Profile | |
| Eugene Jiang | Chairman Officer | Profile |
Already Invested in ABVC Biopharma?
The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.